Literature DB >> 6420119

The activity of ceftazidime, other beta-lactams, and aminoglycosides against Pseudomonas aeruginosa.

K V Rolston, P H Chandrasekar, J L LeFrock, R F Schell.   

Abstract

The inhibitory and bactericidal activities of ceftazidime, cefoperazone, ceftriaxone, piperacillin, and five aminoglycosides were determined against 50 tobramycin-susceptible and 25 multidrug-resistant isolates of Pseudomonas aeruginosa. Ceftazidime was the most active beta-lactam and tobramycin the most active aminoglycoside. The combination of piperacillin and tobramycin was synergistic in most cases. The combination of cephalosporin and tobramycin showed mostly addition or indifference, as did combination of two beta-lactams. No antagonism was observed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420119     DOI: 10.1159/000238241

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

1.  Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria.

Authors:  S M Shrivastava; S K Shukla; M Chaudhary
Journal:  Folia Microbiol (Praha)       Date:  2009-11-24       Impact factor: 2.099

2.  Antibiotic susceptibility of clinical isolates of Pseudomonas aeruginosa.

Authors:  C Cervantes-Vega; J Chavez; M G Rodriguez
Journal:  Antonie Van Leeuwenhoek       Date:  1986       Impact factor: 2.271

Review 3.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 4.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

5.  In vitro activity of ceftazidime in combination with other antibiotics.

Authors:  C Simon; G Littschwager
Journal:  Infection       Date:  1985 Jul-Aug       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.